On July 29, UnitedHealth Group (NYSE:UNH) announced a $4 million commitment, funded through the United Health Foundation, to expand the University of Tennessee Health Sciences’ health hub network from 5 locations to 13 across the state by the end of 2027, a buildout expected to reach 200,000 Tennessee residents. It’s a modest sum for a company this size, but it lands as UnitedHealth works to repair a business that fell apart just a year earlier.
Bull Case: Margins Are Turning The Other Way
The repair is showing up in the numbers. UnitedHealth’s medical care ratio, the share of premiums spent on claims, hit 88.9% in 2025, up from 85.5% in 2024, and operating earnings collapsed from $32 billion to $19 billion as a result. That ratio has since started reversing: it came in at 86.7% in the second quarter, below the 88.5% analysts expected, and management is now guiding to 88% for the full year while aiming to beat it. Second-quarter revenue of $112 billion topped the $110.9 billion analysts projected, and adjusted earnings per share of $6.38 came in well above the $4.90 consensus estimate.
UnitedHealth followed that quarter by raising its full-year adjusted EPS guidance to a range of $19.50 to $20, up from its prior forecast of $18.25. The company has also credited restructuring, including exiting unprofitable contracts, and new use of AI to speed up processes. UnitedHealth’s revenue has grown 150% over the past 10 years, a run one analysis tied to healthcare spending rising faster than the economy. The stock has climbed nearly 50% over the past year as the turnaround has taken hold.
Bear Case: Not Everyone Is Convinced Yet
Not every signal points the same way. Berkshire Hathaway bought UnitedHealth stock at an average price around $380 in the second quarter of 2025 and exited the position in the first quarter of 2026 at less than $300, one of the conglomerate’s rare recent losses. On a trailing basis, the stock still isn’t cheap: at a market cap of $380 billion against trailing net income of $14.9 billion, UnitedHealth carries a trailing price-to-earnings ratio of 25.5, a multiple that assumes the margin recovery continues rather than stalls. One analysis put shares at 23 times estimated future earnings and noted the stock would need to climb roughly another 19% to revisit the $500 level it hasn’t traded at since early last year, a bar that leaves little room for the medical care ratio to disappoint the way it did in 2025.
What The Numbers Say Now
UnitedHealth trades at a forward price-to-earnings ratio of 20.58 as of August 7, a discount to its 25.5 trailing multiple, and a sign the market expects the medical care ratio recovery to continue. Short interest sits at a modest 2.13% of the float, suggesting limited organized betting against the turnaround. The hedge fund count tied to the stock fell from 145 to 130 quarter over quarter, a pullback that runs counter to the stock’s rebound.
